Myanmar develops its own Covid-19 medicine

A Myanmar pharma company has produced the first domestically-manufactured Covid-19 medicine, but so far it is only for clinical use for the treatment of early signs of the coronavirus infection and to support a recovery in the patient.

The drug, named Favipac, is being manufactured by Yangon-based Pacific Medical Industries. The company said that it has received regulatory approval for the drug which can be used to initiate rapid recovery from the onset of mild Covid-19 symptoms and reduce the risk of developing a serious illness from this virus.

The company said it worked with both local and foreign scientists to develop the generic drug on the basis of an existing medicine called Avigan widely used in Japan, Russia, China, India, Taiwan, Europe and South America for influenza treatment.

Original drug used for influenza treatment

The original drug, containing the antiviral medication favipiravir, is being manufactured by Japan’s Toyama Chemical and was approved for medical use in Japan in 2014 and later on licensed as a generic drug in China.

Pacific Medical Industries said it will, in a first step, donate 75,000 pills of its Covid-19 medicine to domestic hospitals.

However, some medical experts have reacted critical on the drug, saying there was still insufficient data to prove that it can effectively treat Covid-19.



Support ASEAN news

Investvine has been a consistent voice in ASEAN news for more than a decade. From breaking news to exclusive interviews with key ASEAN leaders, we have brought you factual and engaging reports – the stories that matter, free of charge.

Like many news organisations, we are striving to survive in an age of reduced advertising and biased journalism. Our mission is to rise above today’s challenges and chart tomorrow’s world with clear, dependable reporting.

Support us now with a donation of your choosing. Your contribution will help us shine a light on important ASEAN stories, reach more people and lift the manifold voices of this dynamic, influential region.

$
Personal Info

Donation Total: $10.00

 

 

A Myanmar pharma company has produced the first domestically-manufactured Covid-19 medicine, but so far it is only for clinical use for the treatment of early signs of the coronavirus infection and to support a recovery in the patient. The drug, named Favipac, is being manufactured by Yangon-based Pacific Medical Industries. The company said that it has received regulatory approval for the drug which can be used to initiate rapid recovery from the onset of mild Covid-19 symptoms and reduce the risk of developing a serious illness from this virus. The company said it worked with both local and foreign scientists...

A Myanmar pharma company has produced the first domestically-manufactured Covid-19 medicine, but so far it is only for clinical use for the treatment of early signs of the coronavirus infection and to support a recovery in the patient.

The drug, named Favipac, is being manufactured by Yangon-based Pacific Medical Industries. The company said that it has received regulatory approval for the drug which can be used to initiate rapid recovery from the onset of mild Covid-19 symptoms and reduce the risk of developing a serious illness from this virus.

The company said it worked with both local and foreign scientists to develop the generic drug on the basis of an existing medicine called Avigan widely used in Japan, Russia, China, India, Taiwan, Europe and South America for influenza treatment.

Original drug used for influenza treatment

The original drug, containing the antiviral medication favipiravir, is being manufactured by Japan’s Toyama Chemical and was approved for medical use in Japan in 2014 and later on licensed as a generic drug in China.

Pacific Medical Industries said it will, in a first step, donate 75,000 pills of its Covid-19 medicine to domestic hospitals.

However, some medical experts have reacted critical on the drug, saying there was still insufficient data to prove that it can effectively treat Covid-19.



Support ASEAN news

Investvine has been a consistent voice in ASEAN news for more than a decade. From breaking news to exclusive interviews with key ASEAN leaders, we have brought you factual and engaging reports – the stories that matter, free of charge.

Like many news organisations, we are striving to survive in an age of reduced advertising and biased journalism. Our mission is to rise above today’s challenges and chart tomorrow’s world with clear, dependable reporting.

Support us now with a donation of your choosing. Your contribution will help us shine a light on important ASEAN stories, reach more people and lift the manifold voices of this dynamic, influential region.

$
Personal Info

Donation Total: $10.00

 

 

2 COMMENTS

  1. In India, 40 pharma companies manufacture favipiravir:
    Abbott (Fapvir), Aeon (COFA), Alkem (Alfluenza), Aprazer (Favikast), Avra (generic), BDR (BDFAVI), Biocon (Araflu), Biophore (generic), Blue Cross (FaviBlu), Brinton (Faviton), Cipla (Ciplenza), Converge (Vergiflu), Covalent (Favimax), Divi’s (generic), Dr. Reddy’s (Avigan), FDC (PiFLU and Favenza), Fusion (Xaravir), Glenmark (Fabiflu), Healing Pharma (Fapivir), Hetero (Favivir), Hikal (generic), Indoco Remedies (Fevindo), J.B.Chemicals (Favipill), Jenburkt (Favivent), Lasa (generic), Lee (Faravir), Lupin (Covihalt), Macleods (generic), Mangalam (generic), Micro (Actavir), MSN (Favilow), Mylan (Favtris), Novagen (generic), Optimus (Favicovid), Raghava (generic), Sun (FluGuard), Strides (generic), Tagoor (generic), Vivimed (Favulous), Zenara (Favizen)

    In Bangladesh, 8 pharma companies manufacture favipiravir:
    Beacon (Favipira), Beximco (Viraflu), Biopharma (Biofavi), Eskayef (Favipir), UniMed UniHealth (Unifav), NIPRO JMI (Fluvigan), Square (Favinil), Veritas (Verigan)

    In Turkey, 8 pharma companies manufacture favipiravir:
    Atabay (Favicovir), Awamedica (Fabivir), Koçak Farma (Raviran), Istanbul Pharma (generic), Neutec Pharma (Favimol), Novelfarma (Favira), Santa Farma (Convolyn), World Medicine İlaç (Loqular)

    In China, 5 pharma companies manufacture favipiravir:
    APICMO (generic), Hunan Huateng (generic), Shouyuan Chemical (generic), Sihuan (generic), Zhejiang Hisun (Favilavir)

    In Egypt, 4 pharma companies manufacture favipiravir:
    EIPICO (Epifluver), Eva (Avipiravir), Rameda (Anviziram), Sabaa (generic)

    In Russia, 3 pharma companies manufacture favipiravir:
    Chromis, which is RDIF plus ChemRar (Avifavir), Promomed and Solyur-pharm (Areplivir), R-Pharm (Coronavir)

    In Bolivia, Sigma Pharma manufactures Avifavir (favipiravir)
    In Canada, India-based Dr. Reddy’s Laboratories, Canada’s Appili Therapeutics, and Global Response Aid are working together to get Health Canada to approve Reeqonus (favipiravir) for Canada
    In Costa Rica, the University of Costa Rica manufactures their own favipiravir
    In Hungary, the Hungarian Academy of Sciences and the University of Pécs had been manufacturing favipiravir but now, Egis Pharma manufactures favipiravir
    In Indonesia, PT Kimia Farma manufactures the favipiravir API for PT Beta Pharmacon, which manufactures the Avigan (favipiravir) tablets
    In Iran, Shahid Beheshti Medical University manufactures their own favipiravir
    In Japan, Fujifilm Toyama Chemical manufactures Avigan (favipiravir)
    In Jordan, Sana Pharma manufactures Sancovir (favipiravir)
    In Kazakhstan, a pharma company in Almaty manufactures their own favipiravir
    In Myanmar, AA Medical Pharma, Myanmar Pharma, and Pacific Medical Industries work together to manufacture Favipac (favipiravir)
    In Nepal, Deurali-Janta Pharma manufactures Favir (favipiravir)
    In Pakistan, India-based PharmAlliance manufactures favipiravir for Pakistan
    In the Philippines, Biocare manufactures their own favipiravir
    In Romania, Terapia (Sun Pharma Therapy Cluj) manufactures FluGuard (favipiravir)
    In Taiwan, the Development Center for Biotechnology manufactured their own favipiravir long before COVID-19 first started
    In Thailand, the Government Pharmaceutical Organization (GPO) manufactures their own favipiravir
    In the Ukraine, Microkhim Pharma manufactures Favipiravir-Microkhim (favipiravir)

    In addition, numerous other nations have imported favipiravir for treating COVID-19 but have not manufactured it

  2. These clinical trials reported excellent results in favor of favipiravir:
    https://pubmed.ncbi.nlm.nih.gov/28769016/
    https://pubmed.ncbi.nlm.nih.gov/31822885/
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818889/
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102570/
    https://www.sciencedirect.com/science/article/pii/S2095809920300631
    https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v2.full.pdf
    https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03288-5
    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/russian-drug-to-treat-covid-to-be-delivered-to-hospitals-in-june/articleshow/76131135.cms
    https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1176/5890024
    https://www.sciencedirect.com/science/article/pii/S0377123720301581
    https://www.prnewswire.com/in/news-releases/glenmark-announces-top-line-results-from-phase-3-clinical-trial-of-favipiravir-in-patients-with-mild-to-moderate-covid-19-886962242.html
    https://pubmed.ncbi.nlm.nih.gov/32972430/
    https://www.thedailystar.net/health/news/dhaka-trial-recommends-favipiravir-covid-19-treatment-1928665
    https://www.trialsitenews.com/the-dhaka-trial-clear-cut-evidence-favipiravir-effective-against-covid-19-with-compelling-results/
    https://www.medrxiv.org/content/10.1101/2020.06.24.20133249v1
    https://www.medrxiv.org/content/10.1101/2020.08.25.20181388v1
    https://pubmed.ncbi.nlm.nih.gov/33237663/
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347251/
    https://pubmed.ncbi.nlm.nih.gov/32958718/
    https://aac.asm.org/content/64/12/e01897-20
    http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200529.pdf
    https://pubmed.ncbi.nlm.nih.gov/33037151/

    WHO says, “favipiravir appears to be a relatively safe drug,” remdesivir not:
    https://www.researchgate.net/publication/346972931_Favipiravir_Use_in_COVID-19_Analysis_of_Suspected_Adverse_Drug_Events_Reported_in_the_WHO_Database

    More than 100 very popular drugs that have been approved worldwide, including statins for cholesterol, ACE inhibitors and ARBs for blood pressure, corticosteroids and NSAIDs for pain or inflammation, antibiotics for infections, progestins, anabolic steroids, methotrexate, anti-fungals, anti-virals, chemotherapy drugs, alcoholic drinks, tobacco, and ionizing radiation, ALL CAUSE BIRTH DEFECTS:
    https://www.researchgate.net/profile/Daryl_Lynch/publication/287212052/figure/tbl1/AS:669660978622474@1536671027816/Teratogenic-Medications-Queried-for-During-Study-Period.png
    http://www.emdocs.net/wp-content/uploads/2017/05/Screen-Shot-2017-05-09-at-12.48.32-AM-768×993.png

    Infographics:
    https://i.ytimg.com/vi/JtPHoGNP5Ik/maxresdefault.jpg
    https://m4.healio.com/~/media/images/news/print/infectious-disease-news/2018/07_july/influenza_table_hires.jpg
    https://i.ytimg.com/vi/VuwJOJQcJOs/maxresdefault.jpg
    https://media.springernature.com/original/springer-static/image/chp%3A10.1007%2F978-981-13-9562-8_15/MediaObjects/430783_1_En_15_Fig2_HTML.png
    https://rebelem.com/wp-content/uploads/2018/11/Baloxavir-MOA.png
    https://www.untpikapps.com/wp-content/uploads/2018/08/viruses-free-full-text-ovarian-cycle-diagram.jpg
    https://www.researchgate.net/profile/Guangdi_Li2/publication/303889968/figure/fig13/AS:373073107800071@1465958968561/Tertiary-structures-of-influenza-virus-proteins-matrix-2-neuraminidase-and-RNA.png
    https://microbenotes.com/wp-content/uploads/2020/06/Mechanism-of-Action-of-Favipiravir.jpeg

Leave a Reply